Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 20Active not recruiting 11Withdrawn 6Not yet recruiting 4Terminated 3Completed 3Available 2Suspended 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × balstilimab × Clear all
NCT03894215 2026-03-27

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Agenus Inc.

Phase 2 Terminated
211 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Terminated
4 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms

NCT04156100 2022-03-03

A Study in Subjects With Advanced Solid Tumors

Agenus Inc.

Phase 1 Terminated
19 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡